ALLEGAN, Mich., Oct. 28, 2011 /PRNewswire/ -- Perrigo Company today announced that it will attend the 2011 Annual Meeting of the American College of Allergy, Asthma & Immunology Conference (ACAAI) Nov. 3-8 at the Hynes Convention Center and the Sheraton Boston Hotel in Boston.
The ACAAI is a professional medical organization that promotes excellence in the practice of the medical subspecialty of allergy and immunology. It is comprised of more than 5,000 allergists, immunologists and primary care physicians who care for allergy patients across the nation.
Perrigo is among the top pharmaceutical companies in the world and is the largest manufacturer of “store-brand” over-the-counter (OTC) medicines for the nation’s leading retailers, grocers, club stores and pharmacy chains. The company produces an extensive portfolio of store-brand allergy products that compare to leading national-brands, such as Loratadine tablets (Claritin®), Cetirizine HCl tablets (Zyrtec®), and the most recent non-sedating antihistamine to switch from prescription to over-the-counter, Fexofenadine HCl tablets (Allegra® Allergy). Perrigo’s FDA-approved store-brand portfolio offers consumers savings of at least 20 percent over national-brands.
STORE-BRAND VERSUS NATIONAL-BRAND SAVINGS ON OTC ALLERGY PRODUCTS | ||||
National-Brand** | Store-Brand ** | Savings** 52-week period | ||
Loratadine tablets (Claritin®) 30ct | $22.49 | $9.85 | $153.79 | |
Cetirizine HCl tablets (Zyrtec®) 30ct | $21.13 | $13.95 | $87.36 | |
Fexofenadine HCl tablets (Allegra®) 45ct | $29.19 | $20.69 | $68.94 | |
In addition to offering a number of products in store-brand, Perrigo also offers a full ORx® portfolio (OTC medicines-by-prescription) for patients whose public or private healthcare insurance covers OTC products when they are prescribed by a doctor. Unlike OTCs today, ORx® products are still eligible for pre-tax flexible spending account dollars, which can result in significant additional savings.
Although most prescribers are somewhat familiar with store-brands, perceptions and knowledge of how they are manufactured varies widely. Attendance at the 2011 ACAAI conference gives Perrigo the opportunity to interact with these influential clinicians in a more intimate setting and educate them on the value and quality store-brands offer patients.
“Perrigo has been actively engaging the medical community and having a dialogue about store-brands as part of the overall healthcare picture,” said Joseph Papa, president and CEO of Perrigo. “It was through these conversations that we recognized the particular importance of highlighting our commitment to manufacturing products of exceptional quality. If we expect physicians to feel confident recommending store-brands to their patients, we know we must communicate that every Perrigo drug is held to the same regulatory and quality standards as national-brand drugs. And once they learn more about our company and our products, many do recommend store-brands.”
** Prices and savings based on national averages of major retailers. Actual prices may vary. (SymphonyIRI Group, 52 weeks ending 6/5/11). Calculations are based on per tablet pricing x 1 daily single dose for 365 days.
About Perrigo Company
Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes OTC and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, active pharmaceutical ingredients (API) and pharmaceutical and medical diagnostic products. The Company is the world’s largest store-brand manufacturer of OTC pharmaceutical products and infant formulas. The Company’s primary markets and locations of manufacturing and logistics operations are the United States, Israel, Mexico, the United Kingdom and Australia. Visit Perrigo on the Internet (http://www.perrigo.com).
SOURCE Perrigo Company
